Elon Musk’s Neuralink has raised $650 million to continue advancing its brain implants for patients with paralysis and other disorders, the company said.
The series E funding round included such investors as ARK Invest, DFJ Growth, Founders Fund, G42, Human Capital, Lightspeed, QIA, Sequoia Capital, Thrive Capital, Valor Equity Partners, Vy Capital, according to a June 2 blog post.
Neuralink has secured FDA Breakthrough Device Designation for vision and speech restoration, and is currently conducting clinical trials at Phoenix-based Barrow Neurological Institute, The Miami Project to Cure Paralysis at the University of Miami, University Health Network (Toronto Western Hospital), and Cleveland Clinic Abu Dhabi.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
